Back to search

Article

First results from the UK COVID-19 Serology in Oncology Staff Study (CSOS)

2020-06-23

Abstract excerpt

<h4>Background</h4> The global SARS-CoV-2 (COVID-19) pandemic has caused substantial worldwide mortality. At present, there is no data regarding oncologist-specific SARS-CoV-2 infection/immunity rates in the United Kingdom (UK) which might impact planning for the management of potentially immunosuppressed cancer patients. Here, we present the first results from the COVID-19 Serology in Oncology Staff (CSOS) study...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
b01ad3b9-ac54-51a7-b623-e1ea8ef08dc4
DOI
10.1101/2020.06.22.20136838
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
First results from the UK COVID-19 Serology in Oncology Staff Study (CSOS)DOI 10.1101/2020.06.22.20136838
Scottish COVID CAncer iMmunity Prevalence (SCCAMP) - a longitudinal study of patients with cancer receiving active anti-cancer treatment during the COVID-19 pandemicSemantic proximity
Scottish COVID Cancer Immunity Prevalence (SCCAMP) - a Longitudinal Study of Patients with Cancer Receiving Active Anti-Cancer Treatment During the COVID-19 PandemicSemantic proximity
Seroprevalence study prior and post vaccination in Cancer patients in Principality of Andorra (COVONCO study)Semantic proximity
Characteristics and outcome of SARS-CoV-2 infection in cancer patients.Semantic proximity
SARS-CoV-2 antibody seroprevalence in cancer patients on systemic antineoplastic treatment in the first wave of the COVID-19 pandemic in PortugalSemantic proximity
Incidence and Immunomic Features of Apyretic COVID-19 in Patients Affected by Solid Tumors: a Prospective Cohort Study.Semantic proximity
Anti-SARS-CoV-2 antibody containing plasma improves outcome in patients with hematologic or solid cancer and severe COVID-19 via increased neutralizing antibody activity – a randomized clinical trialSemantic proximity
Interim results of the safety and immune-efficacy of 1 versus 2 doses of COVID-19 vaccine BNT162b2 for cancer patients in the context of the UK vaccine priority guidelinesSemantic proximity
Functional antibody and T-cell immunity following SARS-CoV-2 infection, including by variants of concern, in patients with cancer: the CAPTURE studySemantic proximity
Clinical and laboratory features of COVID-19 illness and outcomes in immunocompromised individuals during the first pandemic wave in Sydney, AustraliaSemantic proximity
Assessing COVID-19 Infection, and Severe Disease Risk in Cancer Patients and Survivors: The Role of Vaccination Status, Circulating Variants, and Comorbidities—A Population-Based Study in Northern ItalySemantic proximity
EVALUATION OF KNOWLEDGE, ATTITUDES AND BEHAVIOURS ABOUT COVID-19 AMONG CANCER PATIENTSSemantic proximity
Select a neighboring publication to make it the new centre.